IL251404B - Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis - Google Patents

Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis

Info

Publication number
IL251404B
IL251404B IL251404A IL25140417A IL251404B IL 251404 B IL251404 B IL 251404B IL 251404 A IL251404 A IL 251404A IL 25140417 A IL25140417 A IL 25140417A IL 251404 B IL251404 B IL 251404B
Authority
IL
Israel
Prior art keywords
osteoporosis
altered
prevention
treatment
aromatic compounds
Prior art date
Application number
IL251404A
Other languages
English (en)
Hebrew (he)
Other versions
IL251404A0 (en
Original Assignee
Liminal Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liminal Biosciences Ltd filed Critical Liminal Biosciences Ltd
Publication of IL251404A0 publication Critical patent/IL251404A0/en
Publication of IL251404B publication Critical patent/IL251404B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/32—Phenylacetic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL251404A 2014-10-10 2017-03-27 Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis IL251404B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462062597P 2014-10-10 2014-10-10
PCT/CA2015/000540 WO2016054728A1 (en) 2014-10-10 2015-10-08 Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis

Publications (2)

Publication Number Publication Date
IL251404A0 IL251404A0 (en) 2017-05-29
IL251404B true IL251404B (en) 2020-11-30

Family

ID=55652429

Family Applications (1)

Application Number Title Priority Date Filing Date
IL251404A IL251404B (en) 2014-10-10 2017-03-27 Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis

Country Status (23)

Country Link
US (2) US20180228750A1 (enExample)
EP (1) EP3203999B1 (enExample)
JP (1) JP6700639B2 (enExample)
KR (1) KR20170066476A (enExample)
CN (1) CN106999456B (enExample)
AR (1) AR102246A1 (enExample)
AU (1) AU2015330645B2 (enExample)
BR (1) BR112017007426A2 (enExample)
CA (1) CA2963354A1 (enExample)
DK (1) DK3203999T3 (enExample)
ES (1) ES2785317T3 (enExample)
IL (1) IL251404B (enExample)
MX (1) MX376873B (enExample)
MY (1) MY194308A (enExample)
PH (1) PH12017500638A1 (enExample)
PL (1) PL3203999T3 (enExample)
PT (1) PT3203999T (enExample)
RU (1) RU2709205C2 (enExample)
SG (1) SG11201702868VA (enExample)
TW (1) TWI699200B (enExample)
UY (1) UY36356A (enExample)
WO (1) WO2016054728A1 (enExample)
ZA (1) ZA201702639B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016054725A1 (en) * 2014-10-10 2016-04-14 Prometic Biosciences Inc. Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
AU2015345943B2 (en) * 2014-11-12 2020-03-19 Liminal Biosciences Limited Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration
CN107683135A (zh) 2015-03-09 2018-02-09 因特克林医疗有限公司 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
KR20190065252A (ko) * 2016-08-18 2019-06-11 인테크린 테라퓨틱스, 아이엔씨. 골 질환 치료용 PPARγ 작용제
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
AU2021356346A1 (en) * 2020-10-06 2023-06-15 Pharmaceutique Ingenew Inc. Substituted aromatic compounds and pharmaceutical compositions thereof
MX2024005982A (es) * 2021-11-17 2024-05-30 Natreon Inc Withania somnifera y asparagus racemosus en el tratamiento de enfermedades posmenopausicas.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200720256A (en) * 2005-05-13 2007-06-01 Synta Pharmaceuticals Corp IL-12 modulatory compounds
EP2427416B1 (en) * 2009-05-04 2016-03-09 Prometic Pharma Smt Limited Substituted aromatic compounds and pharmaceutical uses thereof
BRPI1015118A2 (pt) * 2009-05-04 2016-04-12 Prometic Biosciences Inc sais de ácido pentilfenilacético e usos farmacêuticos dos mesmos
PH12013500763B1 (en) * 2010-10-27 2018-07-04 Prometic Pharma Smt Ltd Phenylketone carboxylate compounds and pharmaceutical uses thereof
CN105997967B (zh) * 2010-10-27 2019-08-23 普罗米蒂克医药Smt有限公司 用于治疗癌症的化合物和组合物
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
TWI689490B (zh) * 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
WO2016054725A1 (en) * 2014-10-10 2016-04-14 Prometic Biosciences Inc. Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis

Also Published As

Publication number Publication date
AR102246A1 (es) 2017-02-15
KR20170066476A (ko) 2017-06-14
BR112017007426A2 (pt) 2018-01-16
CA2963354A1 (en) 2016-04-14
MY194308A (en) 2022-11-27
TW201618762A (zh) 2016-06-01
WO2016054728A1 (en) 2016-04-14
IL251404A0 (en) 2017-05-29
PT3203999T (pt) 2020-04-23
EP3203999B1 (en) 2020-01-08
RU2017116178A (ru) 2018-11-19
DK3203999T3 (da) 2020-03-30
ZA201702639B (en) 2018-06-27
PL3203999T3 (pl) 2020-07-27
UY36356A (es) 2016-06-01
US11185521B2 (en) 2021-11-30
AU2015330645B2 (en) 2020-03-12
PH12017500638A1 (en) 2017-09-25
JP6700639B2 (ja) 2020-05-27
AU2015330645A1 (en) 2017-05-04
CN106999456B (zh) 2020-07-10
SG11201702868VA (en) 2017-05-30
RU2709205C2 (ru) 2019-12-17
MX2017004733A (es) 2017-07-17
ES2785317T3 (es) 2020-10-06
CN106999456A (zh) 2017-08-01
JP2017530180A (ja) 2017-10-12
EP3203999A4 (en) 2018-06-27
EP3203999A1 (en) 2017-08-16
MX376873B (es) 2025-03-07
TWI699200B (zh) 2020-07-21
RU2017116178A3 (enExample) 2019-05-16
US20200237693A1 (en) 2020-07-30
US20180228750A1 (en) 2018-08-16

Similar Documents

Publication Publication Date Title
IL290823A (en) Pharmaceutical compositions for combination therapy
LT3206715T (lt) Kanabidiolio naudojimas tuberozinės sklerozės komplekso gydymui
EP3148532A4 (en) Pharmaceutical combination for the treatment of cancer
IL253854B (en) Mebendazole polymorph for treatment and prevention of tumors
ZA201702639B (en) Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
IL248779A0 (en) Pharmaceutical compositions for treating infectious diseases
ZA201703976B (en) Dihydropyrimidine-2-one compounds and medicinal uses thereof
GB201506654D0 (en) Formulations for inhibition of PCSK9 for the treatment of hypercholesterolemia
HUE051563T2 (hu) Gyógyszerkészítmény rák megelõzésére vagy kezelésére
PL3081228T3 (pl) Iryzyna do leczenia i zapobiegania osteoporozie
SG11201705889VA (en) Prevention or Treatment of Uratic or Gouty Diseases
IL251392B (en) Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes
DE112015002229A5 (de) Formulierungen zur Behandlung von Hyperthyreose
GB201406172D0 (en) Therapy and pharmaceutical composition
PL3377500T3 (pl) Związki oksadiazaspiro do leczenia nadużywania i uzależnienia od narkotyków/leków
EP3156054A4 (en) Medicine for preventing and/or treating stress-induced diseases
HUE047272T2 (hu) Gyógyászati kompozíció rák kezelésére és/vagy megelõzésére
ZA201804588B (en) Pharmaceutical formulations for the treatment of diabetes
EP3219323B8 (en) Pharmaceutical composition for treatment and/or prevention of hepatitis c
PL3193859T3 (pl) Preparaty do leczenia i zapobiegania czerwienieniu po alkoholu i reakcjom nadwrażliwości wywołanym alkoholem
IL251409B (en) Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
PL3164110T3 (pl) Kompozycje farmaceutyczne do leczenia łuszczycy
HK1236421A1 (en) Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes
GB201523012D0 (en) The combination of chinese medicine for treating infantile cough
HK1236134A1 (en) Pharmaceutical combination for the treatment of cancer

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed